353 related articles for article (PubMed ID: 35874675)
1. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
You W; Ouyang J; Cai Z; Chen Y; Wu X
Front Immunol; 2022; 13():827506. PubMed ID: 35874675
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
Wei S; Sun Q; Chen J; Li X; Hu Z
Front Genet; 2022; 13():1068112. PubMed ID: 36579327
[No Abstract] [Full Text] [Related]
3. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
4. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
5. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W
Gene; 2022 Apr; 818():146177. PubMed ID: 35065254
[TBL] [Abstract][Full Text] [Related]
6. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.
Wang Y; Tan H; Yu T; Chen X; Jing F; Shi H
Front Immunol; 2021; 12():755401. PubMed ID: 34917077
[TBL] [Abstract][Full Text] [Related]
7. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
8. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
9. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP
Wang X; Hui S; Tan C; Deng Z; Wang X; Weng W; Zhang M; Ni S; Wang L; Huang D; Wang W; Xu M; Sheng W
Cancer Immunol Immunother; 2023 Jun; 72(6):1763-1778. PubMed ID: 36650362
[TBL] [Abstract][Full Text] [Related]
11. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
12. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
[TBL] [Abstract][Full Text] [Related]
13. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
14. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
15. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma.
Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y
Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349
[TBL] [Abstract][Full Text] [Related]
16. Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma.
Zhai Y; Liu X; Huang Z; Zhang J; Stalin A; Tan Y; Zhang F; Chen M; Shi R; Huang J; Wu C; Wu Z; Lu S; You L; Wu J
Sci Rep; 2023 Jan; 13(1):1373. PubMed ID: 36697459
[TBL] [Abstract][Full Text] [Related]
17. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
[TBL] [Abstract][Full Text] [Related]
18. Constructing a novel gene signature derived from oxidative stress specific subtypes for predicting survival in stomach adenocarcinoma.
Zhou R; Peng N; Li W
Front Immunol; 2022; 13():964919. PubMed ID: 36059494
[TBL] [Abstract][Full Text] [Related]
19. Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.
Wang HK; Xu XH; Wang SM; Zhang HY
Transl Cancer Res; 2024 Jan; 13(1):173-190. PubMed ID: 38410201
[TBL] [Abstract][Full Text] [Related]
20. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.
Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
J Transl Med; 2021 Aug; 19(1):352. PubMed ID: 34404444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]